Clinical Study | Office of Clinical Research

A Phase III Randomized Study Of Adjuvant Ipilimuab Anti-Ctla4 Therapy Versus High-Dose Interferon A-2B For Resected High Risk Melanoma

Posted Date: May 15, 2019

Investigator: Rekha Chaudhary
Type of Study: Drug

This study will determine which approach to treating resected high risk melanoma is more effective. Patients will receive Ipilimumab anti-CTLA4 therapy versus high-dose interferon a-2b after surgery. The study doctors would like to keep track of your medical condition for a period of 15 years after

Criteria:

Eligible Patients Must Have Melanoma That Has Been Surgically Removed

Keywords:

E1609, High Risk , Melanoma, Resected, Surgically Removed

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List